头像

Wangzhiren

Professor,

Tel:

Email:

Department: School of Biomedical Science and Engineering

Office Location:

Research Interests:

  • Biography
  • Education
  • Admission Information
  • Work Experience
  • Social Position
  • Research Areas
  • Courses Taught
  • Research Project
  • Selected Publications
  • Achievements
  • Patent
  • Honor
  • Software achievement

Biography

Education

2011-2016, Sun Yat-Sen University, School of Pharmaceutical Sciences, Ph.D


Admission Information

WorkExperience

2024-Present, South China University of Technology, Professor

2019-2024, The University of Arizona, College of Pharmacy, Postdoctoral Researcher

2017-2018, Sun Yat-Sen University, Associate Researcher

2016-2016, University of California San Diego, Postdoctoral Scholar Researcher


Social Position

Research Areas

The Dr. Wang’s Laboratory has maintained a sustained research focus on the rational design and development of engineered phospholipid-based nanovesicles as modular drug delivery platforms. These biomimetic systems exhibit significant potential to advance tumor immunotherapy through enhanced spatiotemporal control of immune modulation. Furthermore, their tunable physicochemical properties offer novel therapeutic paradigms for targeted intervention in neurodegenerative pathologies. Dr. Wang has authored over 20 peer-reviewed research articles in high-impact journals including Nature Nanotechnology, Nature Cancer, and Nature Communications, as well as leading specialty journals (Biomaterials, Journal of Controlled Release, Journal of Medicinal Chemistry). Additionally, Dr. Wang holds 4 granted patents in China and the United States.


Courses Taught

Research Project

Selected Publications

  • Zhiren Wang,Immunogenic camptothesome nanovesicles comprised by sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy,Nature Nanotechnology ,2021
  • Zhiren Wang,A sphingolipid-derived Paclitaxel nanovesicle enhances efficacy of combination therapies in triple negative breast cancer and pancreatic cancer,Nature Cancer,2025.08.21
  • Zhiren Wang,A sphingolipid-derived paclitaxel nanovesicle for improved cancer therapy,Nature Cancer,2025.09.04
  • Zhiren Wang,Cholesterol-modified sphingomyelin chimeric lipid bilayer for fortified therapeutic delivery,Nature Communications,2024
  • Zhiren Wang,Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy,Nature Communications,2023
  • Zhiren Wang,Camptothesome-based combination nanotherapeutic regimen for improved colorectal cancer immunochemotherapy,Biomaterials,2024
  • Zhiren Wang,Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade,Journal of Controlled Release,2022
  • Zhiren Wang,Design, synthesis, and evaluation of orally bioavailable quinoline–indole derivatives as innovative multitarget-directed ligands: promotion of cell proliferation in the adult murine hippocampus for the treatment of Alzheimer’s disease,Journal of Medicinal Chemistry ,2018
  • Zhiren Wang,Design, synthesis and evaluation of orally available clioquinol-moracin M hybrids as multi-target-directed ligands for cognitive improvement in a rat model of neurodegeneration in Alzheimer’s disease,Journal of Medicinal Chemistry ,2015

Achievements

Patent

Honor

Software achievement